Sudarshan Pharma Exits Subsidiary Ishwari Healthcare

Total consideration of Rs 1.40 crore received for 51% equity stake.
209,100 shares transferred to Amit Jatin Mehta, effectively ending subsidiary status.

Reader Takeaway: Simplified corporate structure via divestment; Rs 1.40 crore liquidity inflow for the company.

What just happened

Sudarshan Pharma Industries Ltd has formally concluded the divestment of its 51% stake in Ishwari Healthcare Private Limited. The transaction involved the transfer of 209,100 equity shares, each with a face value of Rs 10, to the buyer, Mr. Amit Jatin Mehta. The deal, which had been previously announced on 13th August 2026, was executed for a total cash consideration of Rs 1.40 crore.

Why this matters

By divesting its majority stake, Sudarshan Pharma has officially ended its relationship with Ishwari Healthcare, which is no longer classified as a subsidiary. For investors, this represents a deliberate move toward operational consolidation. The immediate financial impact is the realization of Rs 1.40 crore in capital, which may be deployed toward the company’s core business operations or debt management.

What changes now

Sudarshan Pharma’s shareholding in Ishwari Healthcare now stands at 0%. Moving forward, the company’s consolidated financial statements will exclude the performance of Ishwari Healthcare, potentially reducing the complexity of the firm’s reporting structure.

What to track next

Shareholders should monitor upcoming quarterly earnings to observe the impact of this divestment on the company’s cash flow and any updates on how the Rs 1.40 crore proceeds are utilized in the broader business strategy.